Washington Says Goodbye to Pandas Amid Bitter US-China Backdrop 

Mei Xiang, a female Giant Panda, investigates a birthday cake presented to her on his 25th birthday at the National Zoo in Washington, US, July 22, 2023.
Mei Xiang, a female Giant Panda, investigates a birthday cake presented to her on his 25th birthday at the National Zoo in Washington, US, July 22, 2023.
TT

Washington Says Goodbye to Pandas Amid Bitter US-China Backdrop 

Mei Xiang, a female Giant Panda, investigates a birthday cake presented to her on his 25th birthday at the National Zoo in Washington, US, July 22, 2023.
Mei Xiang, a female Giant Panda, investigates a birthday cake presented to her on his 25th birthday at the National Zoo in Washington, US, July 22, 2023.

No matter the distance or the weather, Jane Christensen was determined to see the giant pandas before they left Washington.

Now in her 60s, Christensen told AFP she had been captured by the species' magical cuteness over a half-century ago, when China first gifted two pandas to the United States.

"I've had 'panda-monium' ever since,' she said under a chilly rain outside the Smithsonian National Zoo's panda exhibit - hundreds of miles from her home in Michigan.

All three of the zoo's pandas are leaving for China by the end of the year, bringing at least a temporary end to a decades-old connection between the cuddly animal and the US capital.

The zoo has kicked off a week-long "Panda Palooza" event ahead of the departure, welcoming thousands of fans, many outfitted in panda-themed hats and shirts.

And while the pandas' departure had been expected due to contractual obligations, many can't help but see the shift as reflective of the growing strains between Beijing and Washington.

The first black-and-white furballs arrived from China in 1972, as a gift following then-president Richard Nixon's historic visit to the Communist-led nation.

Recognizing the species' uncanny ability to attract fans -- and a potential source of income for its conservation program -- China continued to loan out pandas to Washington and other zoos around the world, since dubbed "Panda Diplomacy."

At the Smithsonian zoo, millions of dollars have been spent on the pandas' enclosure and studies, especially related to breeding, including a popular 24-hour "Panda Cam" to monitor their behavior and health.

"We've been watching on the live cam every day leading up to this point," said Heidi Greco, who traveled hours by car from Ohio with her family.

Her daughter Stormy, who had on a panda hat and carried a just-bought panda umbrella, is "obsessed with pandas," Greco said.

The family had watched the pandas make some laps around their separate outdoor enclosures, then passed through an indoor viewing area where visitors can watch the animals eat snacks and bamboo up close.

"When I heard that these pandas were leaving, and the Atlanta Zoo pandas were leaving, and there would be no panda bears left in all of North America... (except) one very old one in Mexico, I was really, really upset," said Greco.

Zoo Atlanta, in the southern US state of Georgia, will send its four pandas to China by late 2024.

'Soft power'

Pandas Mei Xiang and Tian Tian arrived in Washington in 2000, and have since had four surviving cubs. Xiao Qi Ji ("Little Miracle" in English) was born in 2020 and will also depart by December.

During Xi Jinping's state visit in 2015, the last by a Chinese leader to the United States, his wife and the US first lady held an official ceremony to unveil the name of panda cub Bei Bei.

Eight years later, with mounting tensions over Taiwan and continuing trade disputes between the two powers, the panda exhibit is about to be closed.

The Chinese government tends to "bestow" pandas on "nations with whom China's relations are on the upswing, as a form of soft power projection," said Kurt Tong, a former high-ranking US diplomat and managing partner of the Asia Group consultancy.

"In that respect, given the current tenor of US-China relations it is not surprising that Chinese authorities are allowing panda contracts with US zoos to expire," Tong said in an email to AFP.

He noted that the loans also help China "augment the panda conservation budget."

The Smithsonian pays $500,000 annually to its Chinese conservation group partner, the zoo said.

The pandas' departure "closes a major chapter of an international animal care and conservation success story," the zoo said in a statement, adding that it "remains committed to continuing its efforts to secure and safeguard a healthy future for giant pandas."

One attendee saying her goodbyes at the zoo highlighted successful efforts to grow the wild population of pandas.

"We've come a long way in getting the numbers back up," said Michaela from Maryland, who had her face painted like a panda. The species remains listed as vulnerable.

As the rain let up, a steady stream of visitors began filling the area around the panda's outdoor enclosure.

Known for being a bit sluggish, the panda made repeated laps around the acre-sized plot, climbing up and down the hills -- making sure everyone got one good, final snapshot.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”